AHPBA Sponsored Consensus Conference on the

Multidisciplinary Treatment of Bile Duct Cancer

Wednesday, January 15, 2014San Francisco Marriott Marquis55 Fourth StreetSan Francisco, California

Multidisciplinary Treatment of Bile Duct Cancer (BDC)Wednesday, January 15, 2014 San Francisco Marriott Marquis

55 Fourth Street • San Francisco, California

GoalThe focus of this consensus conference is the multidisciplinary management of patients with bile duct cancers. The aim of this conference is to review the current indications for surgical treatment, non-surgical interventions, and adjuvant therapy for bile duct cancer. This topic has not previously been discussed in a consensus conference format, and therefore, there is likely to be a high education yield for participants. The format will divide the conference into three sessions, individually focusing on Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer. The program features an expert multispecialty international group of speakers, panelists,

and moderators with extensive experience in the diagnosis, staging, treatment, and research related to the state-of-the-art treatment of patients with bile duct malignancy. The goal of this meeting is to provide a forum to review, discuss, and establish current practice guidelines and consensus statements. At the conclusion of the conference, attendees should leave with a higher level of understanding and competence in the diagnosis and management of these disorders.

Educational ObjectivesAfter attending the conference, participants should be able to- Appropriately apply diagnostic and staging modalities to bile duct cancer patients (Knowledge,

Competence, Performance);- Appropriately select the proper surgical treatment modalities available for the

management of bile duct cancer (Knowledge, Competence, Performance);- Appropriately select and sequence the best multiple interventional and nonsurgical treatment

modalities available for optimal management of bile duct cancer (Knowledge, Competence, Performance, Patient Outcomes);

- Appropriately implement the most up-to-date systemic cytotoxic and biologic strategies in the management of bile duct cancer to improve patient outcomes (Knowledge, Competence, Performance, Patient Outcomes).

Target AudienceThis conference will be beneficial to surgical oncologists, medical oncologists, radiologists, and interventional radiologists.

Educational MethodsLectures – Question and Answer – Panel Discussions – Videos

EvaluationA course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvements activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit DesignationThis activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and The Americas Hepato-Pancreato-Biliary Association. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 7.50 AMA/PRA Category 1 Credits TM . Physicians should only claim the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification CertificatesCertificates awarding AMA/PRA Category 1 Credit TM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

* Not an official event of the 2014 Gastrointestinal Cancers Symposium. Not sponsored or endorsed by any of the co-sponsoring organizations of the 2014 Gastrointestinal Cancers Symposium.

Thomas A. Aloia, MD, Co-ChairThe University of TexasMD Anderson Cancer CenterHouston, Texas

John C. Mansour, MD, Co-ChairThe University of Texas Southwestern Medical CenterDallas, Texas

Sharon M. Weber, MD, Co-ChairUniversity of WisconsinMadison, Wisconsin

Eren Berber, MDCleveland ClinicCleveland, Ohio

William C. Chapman, MDWashington University School of MedicineSt. Louis, Missouri

Alessandro Landskron Diniz, MDAC Camargo Cancer CenterSao Paulo, Brazil

Cristina R. Ferrone, MDMassachusetts General HospitalBoston, Massachusetts

William Hawkins, MDWashington University School of MedicineSt. Louis, Missouri

William R. Jarnagin, MDMemorial Sloan-Kettering Cancer CenterNew York, New York

Byrne Lee, MDCity of HopeDuarte, California

Shishir K. Maithel, MDEmory UniversityAtlanta, Georgia

Program Planning CommitteeNipun B. Merchant, MDVanderbilt University Medical CenterNashville, Tennessee

Carl R. Schmidt, MDThe Ohio State UniversityColumbus, Ohio

Jean-Nicolas Vauthey, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas

Theodore H. Welling, III, MDUniversity of MichiganAnn Arbor, Michigan

Adam Yopp, MDUniversity of Texas Southwestern Medical CenterDallas, Texas

George Zogopoulos, MD, PhDMcGill UniversityMontreal, QuebecCanada

Jill KawulokAHPBALeawood, Kansas

Nonie LowryAHPBALeawood, Kansas

Brigitte M. Taylor, CAPThe University of TexasMD Anderson Cancer CenterHouston, Texas

Constance C. Tierney, CMPThe University of TexasMD Anderson Cancer CenterHouston, Texas

ProgramWednesday, January 15, 2014

7:00–7:50 a.m. Continental Breakfast/Registration

7:50–8:00 Introduction William C. Chapman, MD

8:00–10:30 SESSION I: GALLBLADDER CANCER Moderators: Felipe José Fernández Coimbra, MD;

William R. Jarnagin, MD Panelists: Rachna T. Shroff, MD; Elijah Dixon, MD;

Jennifer Knox, MD

8:00–8:20 Pathologic Evaluation for Patients With Gallbladder Polyps and Suspicion of Early Stage Gallbladder Cancer

Juan Carlos Roa, MD, MSc

8:20–8:30 Discussion

8:30–8:50 Evaluation and Management of the Patient Presenting With a Gallbladder Mass

Nicolas Járufe Casis, MD

8:50–9:00 Discussion

9:00–9:20 Incidentally Discovered Gallbladder Cancer:

The Gallbladder is Out, Now What Do We Do?

Shishir K. Maithel, MD

9:20–9:30 Discussion

9:30–9:50 Advances in Neoadjuvant and Adjuvant Chemotherapy and Radiation

Approaches to Gallbladder Cancer Milind Javle, MD

9:50–10:00 Discussion

10:00-10:30 Break

10:30a.m.–12:30 p.m. SESSION II: INTRAHEPATIC CHOLANGIOCARCINOMA (IHCCA) Moderators: Masaru Miyazaki, MD; Sharon M. Weber, MD Panelists: Ghassan K. Abou-Alfa, MD; Michael A. Choti, MD, MBA;

Michael I. D’Agelica, MD; Jeff Geschwind, MD

10:30–10:50 Recommendations for Diagnosis and Staging of IHCCA Timothy M. Pawlik, MD, MPH, PhD

10:50–11:00 Discussion

11:00–11:20 Local-Regional Treatment Strategies for IHCCA Dario Ribero, MD

11:20–11:30 Discussion

11:30–11:50 Hepatocholangiocarcinoma: Defining and Treating An Emerging Entity

Norihiro Kokudo, MD, PhD

11:50–Noon Discussion

Noon–12:20 Chemotherapy and Radiation Therapy for IHCCA Eileen M. O’Reilly, MD

12:20–12:30 p.m. Discussion

12:30–1:30 Lunch at the Movies: Case Presentations With Video Moderators: David M. Nagorney, MD; Paul D. Greig, MD Invited Presenters: Thomas A. Aloia, MD; Julie K. Heimbach, MD;

William R. Jarnagin, MD; Nicolas Járufe Casis, MD; Norihiro Kokudo, MD, PhD; Masaru Miyazaki, MD; Masato Nagino, MD

1:30–3:30 SESSION III: HILAR CHOLANGIOCARCINOMA Moderators: John C. Mansour, MD; Jean-Nicolas Vauthey, MD Panelists: Alessandro Landskron Diniz, MD; Christopher E. Forsmark, MD

Andrew X. Zhu, MD, PhD 1:30–1:50 Multimodality Evaluation of Patients With Suspected

Hilar Cholangiocarcinoma: Including When to Proceed Without a Tissue Diagnosis

Thomas A. Aloia, MD

1:50–2:00 Discussion

2:00–2:20 Transplantation for Hilar Cholangiocarcinoma With and Without PSC

Julie K. Heimbach, MD

2:20–2:30 Discussion

2:30–2:50 Resectional Strategies for Hilar Cholangiocarcinoma Including Vascular Resection and the Concept of ‘No-Touch’ Masato Nagino, MD

2:50–3:00 Discussion

3:00–3:20 Traditional and Novel Chemotherapy and Radiation Approaches to Hilar Cholangiocarcinoma

Christopher Crane, MD

3:20–3:30 Discussion

3:30–3:40 p.m Closing Comments Sharon M. Weber, MD

Ghassan K. Abou-Alfa, MDMemorial Sloan-Kettering Cancer CenterWeill Medical College at Cornell UniversityNew York, New York

Thomas A. Aloia, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas

William C. Chapman, MDWashington University School of MedicineSt. Louis, Missouri

Michael A. Choti, MD, MBAUniversity of Texas SouthwesternDallas, Texas

Felipe José Fernández Coimbra, MDAC Camargo HospitalSao Paulo, Brazil

Christopher Crane, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas

Michael I. D’Angelica, MDMemorial Sloan-Kettering Cancer HospitalNew York, New York

Alessandro Landskron Diniz, MDAC Camargo Cancer CenterSao Paulo, Brazil

Elijah Dixon, MDUniversity of CalgaryCalgary, Alberta, Canada

Christopher E. Forsmark, MDUniversity of Florida College of MedicineGainesville, Florida

Jeff Geschwind, MDJohns Hopkins UniversitySchool of MedicineBaltimore, Maryland

Paul D. Greig, MDUniversity of TorontoToronto, Ontario, Canada

Julie K. Heimbach, MDMayo ClinicRochester, Minnesota

William R. Jarnagin, MDMemorial Sloan-Kettering Cancer CenterNew York, New York

Nicolas Járufe Casis, MDPontificia Unversidad Catolica de ChileSantiago, Chile

Milind Javle, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas

Registration InformationOn-site registration opens at 7:00 a.m. on Wednesday, January 15, 2014 at the San Francisco Marriott Marquis. The opening session of the conference will begin at 7:50 a.m. and the conference will adjourn at 3:40 p.m. on Wednesday, January 15, 2014. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees.

The deadline for advance registration is January 6, 2014.

There are three ways to register:• Mailto:CME/ConferenceManagement–Unit1381,TheUniversityofTexas

MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439• Faxto:713-794-1724• On-lineatwww.mdanderson.org/conferences

We accept the following forms of payment:• Check(payablethroughU.S.banksonly)• MoneyOrder• CreditCards(MasterCard,VISA,andAmericanExpress)• Cash(on-siteregistration)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee.

The full conference registration fee includes the tuition, abstract book, breaks, and lunch.

Refund/Cancellation Policy: The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 6, 2014. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified either by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, contact CME/Conference Management at 713-792-2223 or 866-849-5866.

Jennifer Knox, MD, MScUniversity of Toronto Princess MargaretToronto, Ontario, Canada

Norihiro Kokudo, MD, PhDUniversity of Tokyo Graduate School of MedicineTokyo, Japan

Shishir K. Maithel, MDEmory UniversityAtlanta, Georgia

John C. Mansour, MDUniversity of Texas Southwestern Medical CenterDallas, Texas

Masaru Miyazaki, MDChiba University Graduate School of MedicineChiba, Japan

Masato Nagino, MD, PhDNagoya University Graduate School of MedicineNagoya, Japan

David M. Nagorney, MDMayo Clinic College of MedicineRochester, Minnesota

Eileen M. O’Reilly, MDMemorial Sloan-Kettering Cancer CenterNew York, New York

Timothy M. Pawlik, MD, MPH, PhDJohns Hopkins HospitalBaltimore, Maryland

Dario Ribero, MDOspedale Ordine Mauriziano “Umberto I”Torino, Italy

Juan Carlos Roa, MD, MScPontificia Universidad Catolica de ChileSantiago, Chile

Rachna T. Shroff, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas

Jean-Nicolas Vauthey, MDThe University of TexasMD Anderson Cancer CenterHouston, Texas

Sharon M. Weber, MDUniversity of WisconsinMadison, Wisconsin

Andrew X. Zhu, MD, PhDMassachusetts General HospitalHarvard Medical SchoolBoston, Massachusetts

Faculty

Special AssistanceContact the Department of CME/Conference Management at 713-792-2223 or 866-849-5866 if you have any special dietary or ADA accommodation needs.

AccommodationsIf you are attending the 2014 Gastrointestinal Cancers Symposium, hotel rooms are available at the San Francisco Marriott Marquis, 55 Fourth Street, San Francisco, California. Reserve a room through the Symposium website at gicasym.org.

Ground TransportationThe hotel is approximately 14 miles from San Francisco International Airport and 20 miles from the Oakland Airport. Taxis are available at the approximate price of $40 one way from SFO and $60 one way from Oakland. Super Shuttle is also available. Please call 415-558-8500 or book on line at www.supershuttle.com.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chair for consideration.

THIS

IS N

OT A

SEL

F-M

AILE

R

ADDR

ESS

TO:

AHPB

A Sp

onso

red

Cons

ensu

s Co

nfer

ence

on

the

Mul

tidis

cipl

inar

y Tr

eatm

ent o

f Bi

le D

uct C

ance

r

Depa

rtmen

t of C

ME/

Conf

eren

ce M

anag

emen

t – U

nit 1

381

The

Univ

ersi

ty o

f Tex

as M

D An

ders

on C

ance

r Cen

ter

PO B

ox 3

0143

9, H

oust

on, T

X 77

230-

1439

or fa

x to

713

-794

-172

4M

ake

chec

k or

mon

ey o

rder

pay

able

to:

The

Univ

ersi

ty o

f Tex

as M

D An

ders

on C

ance

r Cen

ter

FULL

CO

NFE

RE

NC

ER

EG

IST

RA

TIO

N F

EE

1 P

ostm

arke

d by

1/07

/14 .

........

...$ 2

60.00

1 P

ostm

arke

d af

ter 1

/07/

14 ...

....$ 3

00.00

1 Tr

aine

es ...

........

........

........

........

..$12

5.00

(m

ust p

rovid

e le

tter f

rom

Dire

ctor

)

CO

NFE

REN

CE

REG

ISTR

ATI

ON

- 06

38/1

1084

5/30

0706

38

AHPB

A Sp

onso

red

Cons

ensu

s Con

fere

nce o

n th

eM

ultid

iscip

linar

y Tre

atm

ent o

f Bi

le D

uct C

ance

r - Ja

nuar

y 15,

2014

Last

Nam

e

Fi

rst

M

I

H

ighe

st D

egre

e

Depa

rtmen

t (in

clud

e bo

x no

.)

Sp

ecia

lty

Inst

itutio

n

Ph

ysic

ian

Stre

et

City

S

tate

/For

eign

Cou

ntry

/Zip

or M

ail C

ode

Dayt

ime

Phon

e (w

ith a

rea

code

)

Cel

l Pho

ne (w

ith a

rea

code

)

F

ax (w

ith a

rea

code

)

E-m

ail A

ddre

ss (

plea

se p

rint)

Char

ge th

e fo

llow

ing:

oVI

SA

o

Mas

terC

ard

oAm

eric

an E

xpre

ss

Cred

it Ca

rd N

umbe

r

Exp

iratio

n Da

te

Busi

ness

Uni

t

D

epar

tmen

t

Fun

d Gr

oup*

F

und

F

und

Type

Cred

it Ca

rd H

olde

r Nam

e (F

irst/

Last

)

Cre

dit C

ard

Hold

er B

illin

g Ad

dres

s &

ZIP

Cod

e

Auth

orize

d Si

gnat

ure

REQU

IRED

for c

redi

t car

d or

IDT

MD

Ande

rson

Em

ploy

ee ID

No.

(REQ

UIRE

D)

IDT

Appr

over

Nam

e (F

irst/

Last

) ple

ase

prin

t

I

DT A

ppro

ver E

-mai

l

oYe

s

o

No

MD

And

erso

n In

terd

epar

tmen

tal T

rans

fer (

IDT)

No.

: *F

und

Grou

p 90

will

not

be

acce

pted

Emer

genc

y Co

ntac

t

P

hone

(with

are

a co

de)

Depa

rtmen

t of C

ME/

Conf

eren

ce M

anag

emen

t - U

nit 1

381

The

Univ

ersi

ty o

f Tex

as M

D An

ders

on C

ance

r Cen

ter

# 17

6700

/110845/30070638

PO B

ox 3

0143

9Ho

usto

n, T

X 77

230-

1439

Non

-Pro

fit O

rg.

U.S.

Pos

tage

P A

I DHo

usto

n, T

XPe

rmit

No.

705

2